Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 1
1994 5
1995 3
1996 1
1997 1
1998 2
1999 1
2000 1
2001 5
2002 4
2003 3
2004 4
2005 4
2007 1
2008 1
2009 2
2011 1
2013 1
2014 2
2015 2
2016 1
2018 1
2019 6
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.
Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE. Dylgjeri E, et al. Among authors: Filvaroff EH. Clin Cancer Res. 2019 Sep 15;25(18):5623-5637. doi: 10.1158/1078-0432.CCR-18-2207. Epub 2019 Jul 2. Clin Cancer Res. 2019. PMID: 31266833
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. Kothari V, et al. Among authors: Filvaroff EH. Clin Cancer Res. 2019 Sep 15;25(18):5608-5622. doi: 10.1158/1078-0432.CCR-18-2387. Epub 2019 Jul 2. Clin Cancer Res. 2019. PMID: 31266829 Free PMC article.
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Thijssen R, et al. Among authors: Filvaroff EH. Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27. Blood. 2016. PMID: 27235137 Clinical Trial.
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. Munster P, et al. Among authors: Filvaroff EH. Cancer Manag Res. 2019 Dec 13;11:10463-10476. doi: 10.2147/CMAR.S208720. eCollection 2019. Cancer Manag Res. 2019. PMID: 31853198 Free PMC article.
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. Wolin E, et al. Among authors: Filvaroff EH. PLoS One. 2019 Sep 17;14(9):e0221994. doi: 10.1371/journal.pone.0221994. eCollection 2019. PLoS One. 2019. PMID: 31527867 Free PMC article. Clinical Trial.
Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).
Hollebecque A, de Bono JS, Plummer R, Isambert N, Martin-Romano P, Baudin E, Mora S, Filvaroff E, Lamba M, Nikolova Z. Hollebecque A, et al. Among authors: Filvaroff E. Ann Oncol. 2019 Feb;30 Suppl 1:i4. doi: 10.1093/annonc/mdz029. Epub 2020 Jan 8. Ann Oncol. 2019. PMID: 32081155 Free article. No abstract available.
A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.
Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, Dey J, Carleton M, Beirne E, Pedro KD, Ditzler SH, Girard EJ, Deckwerth TL, Bertout JA, Meleo KA, Filvaroff EH, Chopra R, Press OW, Olson JM. Klinghoffer RA, et al. Among authors: Filvaroff EH. Sci Transl Med. 2015 Apr 22;7(284):284ra58. doi: 10.1126/scitranslmed.aaa7489. Sci Transl Med. 2015. PMID: 25904742 Free PMC article.
Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.
Aronchik I, Dai Y, Labenski M, Barnes C, Jones T, Qiao L, Beebe L, Malek M, Elis W, Shi T, Mavrommatis K, Bray GL, Filvaroff EH. Aronchik I, et al. Among authors: Filvaroff EH. Mol Cancer Res. 2019 Feb;17(2):642-654. doi: 10.1158/1541-7786.MCR-17-0554. Epub 2018 Oct 1. Mol Cancer Res. 2019. PMID: 30275173 Free article.
Bone remodelling: a signalling system for osteoclast regulation.
Filvaroff E, Derynck R. Filvaroff E, et al. Curr Biol. 1998 Sep 24;8(19):R679-82. doi: 10.1016/s0960-9822(98)70434-8. Curr Biol. 1998. PMID: 9768352 Free article. Review.
53 results
Jump to page
Feedback